Galmed Pharmaceuticals (GLMD) Share-based Compensation (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Share-based Compensation of $156000.0 for Q1 2026, up 54.46% year-over-year from $101000.0 in Q1 2025, and up 201.3% quarter-over-quarter from -$154000.0 in Q4 2025.
Galmed Pharmaceuticals (GLMD) Share-based Compensation (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Share-based Compensation history runs 14 years deep, the most recent figure standing at $156000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 54.46% year-over-year to $156000.0; the TTM figure through Mar 2026 stood at $207000.0 (up 659.46% YoY), while the FY2025 annual figure was $800000.0, up 14.29% from the prior year.
- Share-based Compensation for Q1 2026 stood at $156000.0, up from -$154000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $457000.0 in Q1 2022, with the low at -$400000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $156000.0 (2026), against an average of $147705.9.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 305.13% in 2024, then soared 61.5% in 2025.
- Galmed Pharmaceuticals' Share-based Compensation stood at $182000.0 in 2022, then increased by 7.14% to $195000.0 in 2023, then slumped by 305.13% to -$400000.0 in 2024, then jumped by 61.5% to -$154000.0 in 2025, then soared by 201.3% to $156000.0 in 2026.
- Business Quant data shows GLMD's Share-based Compensation at $156000.0 in Q1 2026, -$154000.0 in Q4 2025, and $105000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.34 Mn | -9.54 Mn | - | 156,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156,000.00 |
| Mar 31, 2026 | 156,000.00 |
| Dec 31, 2025 | -154,000.00 |
| Dec 31, 2025 | -154,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | -400,000.00 |
| Dec 31, 2024 | -400,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Dec 31, 2023 | 195,000.00 |